Literature DB >> 31912975

Gamma-glutamyl transferase to albumin ratio as a novel predictor of bleeding events and mortality in patients after percutaneous coronary intervention: A retrospective cohort study.

Ying-Ying Zheng1,2, Ting-Ting Wu2, You Chen2, Xian-Geng Hou2, Yi Yang2, Xiang Ma2, Yi-Tong Ma2, Jin-Ying Zhang1, Xiang Xie2.   

Abstract

OBJECTIVES: To determine whether gamma-glutamyl transferase (GGT) to albumin ratio (GAR) independently predicts mortality and bleeding events in coronary artery disease (CAD) patients who undergo percutaneous coronary intervention (PCI).
BACKGROUND: Serum GGT and albumin levels have been associated with CAD risk and mortality. However, more analysis is needed to determine their predictive relationship with adverse outcomes.
METHODS: In total, 5,638 patients from a large retrospective cohort study were enrolled from January 2008 to December 2016 and divided into two groups (GAR <0.62, n = 2,712 and GAR ≥0.62, n = 2,926). The average follow-up time was 35.9 ± 22.6 months. Multivariate Cox regression analyses were performed to determine the risk of all-cause mortality and bleeding events associated with GAR.
RESULTS: The low-GAR group had a significantly higher number of all-cause mortality (p = .016) and bleeding events (p = .010) than the high-GAR group. Multivariate Cox regression analyses showed that the risk of all-cause death and bleeding events decreased by 23.8% (hazard risk [HR] = 0.762 95% confidence interval [CI]: 0.601-0.966, p = .025) and 39.4% (HR = 00.616, 95% CI: 0.446-0.852, p = .003), respectively, in the high-GAR group. In patients with acute coronary syndrome, the risk of bleeding events decreased by 57.3% in the high-GAR group (HR = 0.427, 95% CI: 0.234-0.781, p = .006). In patients with stable coronary heart disease, the risk of all-cause death decreased 28.6% (HR = 0.714, 95% CI: 0.540-0.944, p = .018) in the high-GAR group.
CONCLUSION: GAR was an independent and novel predictor of mortality and bleeding events in CAD patients who underwent PCI.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  bleeding; gamma-glutamyl transferase; gamma-glutamyl transferase to albumin ratio; mortality; percutaneous coronary intervention

Mesh:

Substances:

Year:  2020        PMID: 31912975     DOI: 10.1002/ccd.28696

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

1.  Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank.

Authors:  Frederick K Ho; Lyn D Ferguson; Carlos A Celis-Morales; Stuart R Gray; Ewan Forrest; William Alazawi; Jason Mr Gill; Srinivasa Vittal Katikireddi; John Gf Cleland; Paul Welsh; Jill P Pell; Naveed Sattar
Journal:  EClinicalMedicine       Date:  2022-05-12

2.  The Fibrinogen-to-Albumin Ratio Is Associated With Outcomes in Patients With Coronary Artery Disease Who Underwent Percutaneous Coronary Intervention.

Authors:  Da-Peng Zhang; Xiao-Feng Mao; Ting-Ting Wu; You Chen; Xian-Geng Hou; Yi Yang; Xiang Ma; Jin-Ying Zhang; Yi-Tong Ma; Xiang Xie; Ying-Ying Zheng
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

3.  ADS Score as a Novel Predictor of Outcomes in Patients Who Underwent Percutaneous Coronary Intervention.

Authors:  Wen-Jing Zhang; Gang-Qiong Liu; Jia-Hong Shangguan; Xiao-Dan Zhu; Wei Wang; Qian-Qian Guo; Jian-Chao Zhang; Kai Wang; Zhi-Yu Liu; Feng-Hua Song; Lei Fan; Ling Li; Ying-Ying Zheng; Jin-Ying Zhang
Journal:  Front Cardiovasc Med       Date:  2021-12-13

4.  High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort.

Authors:  Peizhi Wang; Deshan Yuan; Ce Zhang; Pei Zhu; Sida Jia; Ying Song; Xiaofang Tang; Jingjing Xu; Tianyu Li; Guyu Zeng; Xueyan Zhao; Yuejin Yang; Bo Xu; Runlin Gao; Jinqing Yuan
Journal:  Cardiovasc Diabetol       Date:  2022-03-21       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.